0.00Open0.00Pre Close0 Volume0 Open Interest7.50Strike Price0.00Turnover1249.76%IV-697.87%PremiumJul 19, 2024Expiry Date6.56Intrinsic Value100Multiplier6DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.6391Delta0.2341Gamma0.14Leverage Ratio-0.0435Theta-0.0009Rho-0.09Eff Leverage0.0005Vega
Passage Bio Stock Discussion
• $DBV Technologies(DBVT.US)$ +23.5% (positive topline results from Phase 3 EPITOPE Trial)
• $Aldeyra Therapeutics(ALDX.US)$ +19.2% (achieves primary endpoint in phase 3 tranquility-2 trial)
• $MediciNova(MNOV.US)$ +11.9% (top-line results from phase 2 clinical trial of MN-166)
• $Torrid(CURV.US)$ +11% (In reaction to earnings/guidance)
• $Novavax(NVAX.US)$ +10.1% (FDA advisory committee recommends EUA for its COVID-19 v...
- $Consolidated Communications(CNSL.US)$ +14.6%: Searchlight affirms 34.6% active holding; to evaluate the possibility of a further investment in or full acquisition.
- $Voyager Therapeutics(VYGR.US)$ +12.2%: agrees to licensing option with $Novartis AG(NVS.US)$; Voyager receives $54 million upfront.
- $Aegon Ltd(AEG.US)$ +6%: provides update on Russian and Belarusian investments following invasion of Ukraine.
- $AZZ Inc(AZZ.US)$ +...
$TransEnterix Inc(TRXC.US)$
$Clovis Oncology(CLVS.US)$
$3D Systems(DDD.US)$
$Revolve Group(RVLV.US)$
$Passage Bio(PASG.US)$
$TransEnterix Inc(TRXC.US)$
$Clovis Oncology(CLVS.US)$
$3D Systems(DDD.US)$
$Revolve Group(RVLV.US)$
$Passage Bio(PASG.US)$
No comment yet